Symptoms
The manifestations of fentanyl overdose are an extension of its pharmacologic actions, the most serious effect being respiratory depression.
Treatment
For management of respiratory depression, immediate countermeasures include removing the Дюрогезик Матрикс system and physically or verbally stimulating the patient. These actions can be followed by administration of a specific opioid antagonist such as naloxone, based on the clinical judgment of the treating health care professional. Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist. The half-life of the antagonist may be short; therefore, repeated administration or infusion of the antagonist may be necessary. Reversal of the narcotic effect may also result in acute onset of pain and release of catecholamines.
If the clinical situation warrants, a patent airway should be established and maintained, possibly with an oropharyngeal airway or endotracheal tube. Oxygen should be administered and respiration assisted or controlled, as appropriate. Adequate body temperature and fluid intake should also be maintained.
If severe or persistent hypotension occurs, hypovolaemia should be considered and the condition should be managed with appropriate parenteral fluid therapy or other interventions as needed, based upon the clinical judgment of the treating health care professional.
Severe respiratory depression or cystic fibrosis.
Not applicable.
Summary of the safety profile
The most commonly reported adverse reactions were nausea, vomiting, and application site reactions such as erythema and pruritus. These were mostly of mild to moderate severity. The most serious adverse reactions reported were hypotension and apnoea and all patients should be closely monitored for these.
Tabulated list of adverse reactions
The following adverse reactions have been reported with Дюрогезик Матрикс during clinical studies and post marketing experience. All adverse reactions are listed by System Organ Class and frequency: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); and rare (>1/10,000 to <1/1,000).
| System Organ Class | Very Common | Common | Uncommon | Rare |
| Infections and infestations | Rhinitis | |||
| Blood and lymphatic system disorders | Anaemia | |||
| Metabolism and nutrition disorders | Decreased appetite | Hypocalcaemia Hypoglycaemia Hypokalaemia | ||
| Psychiatric disorders | Insomnia | Abnormal dreams Agitation Anxiety Confusional state Hallucination Nervousness | Depression Thinking abnormal thoughts | |
| Nervous system disorders | Dizziness Headache | Migraine Paraesthesia Somnolence Syncope | Dysgeusia Hypoaesthesia | |
| Eye disorders | Vision blurred | |||
| Ear and labyrinth disorders | Vertigo | |||
| Cardiac disorders | Tachycardia | Bradychardia | ||
| Vascular disorders | Hypotension | Hypertension Orthostatic hypotension, Vasodilitation | ||
| Respiratory, thoracic and mediastinal disorders | Hypoxia | Apnoea Cough Dyspnoea Hiccups Hypoventilation | Lung disorder | |
| Gastrointestinal disorders | Nausea Vomiting | Constipation Abdominal pain | Dry mouth Dyspepsia Flatulence Ileus | Abdominal distension Diarrhoea Eructation |
| Skin and subcutaneous tissue disorders | Pruritus | Rash Hyperhidrosis | ||
| Musculoskeletal and connective tissue disorders | Back pain Pain in extremity | Hypertonia Myalgia | ||
| Renal and urinary disorders | Urinary retention | Oliguria | Dysuria | |
| General disorders and administration site conditions | Application site erythema | Application site oedema Application site pruritus Application site reaction Application site vesicles Pyrexia | Application site pain Application site dryness Application site papules Asthenia Chills Application site reaction Pain | Chest pain Malaise Application site paraesthesia Injection site oedema Injection site pain Oedema |
| Injury, poisoning and procedural complications | Wound complication | |||
| Surgical and medical procedures | Gastrointestinal disorder therapy |
Paediatric population
Data on Дюрогезик Матрикс in paediatrics is limited to information from a single clinical trial. In this study 28 paediatric patients, 6 to 16 years old, were treated with Дюрогезик Матрикс fentanyl 40 micrograms after experiencing inadequate analgesia with Дюрогезик Матрикс fentanyl 25 micrograms. Among these patients, the incidence of nausea was similar to adult patients; however, vomiting (32.1%) and fever (60.7%) were each reported at a higher incidence in paediatric patients relative to adults. In summary, the limited size of the overall paediatric exposure is insufficient to guide safe and effective dosing of Дюрогезик Матрикс in patients younger than 18 years of age.
Elderly population
Elderly patients (> 65 years) made up 28% (499/1763) of the total controlled clinical trial exposure to Дюрогезик Матрикс 40 micrograms, with approximately 10% (174/1763) of exposures being in patients > 75 years. No overall differences were observed in the safety of Дюрогезик Матрикс fentanyl 40 micrograms in elderly patients (> 65 years including a subpopulation > 75 years) and adult patients for all controlled studies. Thus, the adverse reaction profile does not suggest a meaningful difference in safety compared to patients younger than 65 years of age.
Obese patients
In the controlled clinical trial population, the adverse reaction profile in patients with BMI > 40 (86/1436 or 6%) showed no meaningful difference relative to patients with BMI ≤ 40. However, caution is recommended in these patients.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity.
Standard reproductive and developmental toxicity studies have been carried out using parenteral administration of fentanyl. In a rat study fentanyl did not influence male fertility. Studies with female rats revealed reduced fertility and enhanced embryo mortality.
Effects on the embryo were due to maternal toxicity and not to direct effects of the substance on the developing embryo. There was no indication of teratogenic effects in studies in two species (rats and rabbits). In a study on pre- and postnatal development the survival rate of offspring was significantly reduced at doses which slightly reduced maternal weight. This effect could either be due to altered maternal care or a direct effect of fentanyl on the pups. Effects on somatic development and behaviour of the offspring were not observed.
Mutagenicity testing in bacteria and in rodents yielded negative results. Fentanyl induced mutagenic effects in mammalian cells in vitro, comparable to other opioid analgesics. A mutagenic risk for the use of therapeutic doses seems unlikely since effects appeared only at high concentrations.
A carcinogenicity study (daily subcutaneous injections of fentanyl hydrochloride for two years in Sprague Dawley rats) did not induce any findings indicative of oncogenic potential.
Дюрогезик Матрикс is indicated for the management of acute moderate to severe post-operative pain in adult patients.
Pharmacotherapeutic group: Analgesics; phenylpiperidine derivatives; ATC code: N02AB03.
Mechanism of action
Fentanyl is an opioid analgesic, interacting predominantly with the opioid μ-receptor.
Pharmacodynamic effects
Its primary therapeutic actions are analgesia and sedation. Its secondary pharmacological effects are respiratory depression, bradycardia, hypothermia, constipation, miosis, physical dependence and euphoria.
Clinical efficacy and safety
The efficacy and safety of Дюрогезик Матрикс for treatment of acute, moderate to severe postoperative pain was evaluated in seven controlled studies in 1763 Дюрогезик Матрикс patients: three placebo-controlled studies and four active-controlled studies. The placebo-controlled trials included 791 patients that were predominantly female (72%), Caucasian (82%), with a mean age of 45-54 years (range, 18-90 years), and primarily comprised of surgeries including lower abdominal (including pelvic) and orthopedic bone procedures. Patients were enrolled shortly after major surgery if they were not opioid tolerant, were expected to have an uncomplicated recovery, and required at least 24 hours of parenteral opioid treatment. Long-lasting or any non-opioid analgesics were not permitted. Patients were initially titrated to comfort with intravenous fentanyl or morphine, at which point they were randomized to Дюрогезик Матрикс or a matching placebo system. During the first 3 hours post-enrollment, patients could supplement with bolus intravenous fentanyl given, as needed, to achieve comfort. After this point 727 patients remained in the studies using only the Дюрогезик Матрикс or control system, and were evaluated for efficacy.
The primary endpoint in each placebo-controlled study was the proportion of withdrawals due to inadequate analgesia during the period from 3 to 24-hours after Дюрогезик Матрикс application. As illustrated in Table 1 below, Дюрогезик Матрикс (fentanyl hydrochloride) was superior to placebo in all studies. Additional analyses suggest that the surgical procedure type did not influence the trends in efficacy endpoints and the efficacy of Дюрогезик Матрикс was similar across the range of body mass indices studied (< 25 to > 40 kg/m2 Body Mass Index).
Table 1: Placebo-controlled Trials (N=727) Patients | |||
| Percent (n) of patients who withdrew due to inadequate analgesia Hours 3-24 | |||
| Study | Дюрогезик Матрикс n=454 | Placebo n=273 | p-value |
| C-2001-011 | 27 % (64/235) | 57 % (116/204) | <0.0001 |
| C-2000-008 | 25 % (36/142) | 40 % (19/47) | 0.049 |
| C-95-016 | 8 % (6/77) | 41 % (9/22) | 0.0001 |
Дюрогезик Матрикс was also evaluated in four active-control trials (predominantly female (65%), Caucasian (85%), with a mean age of 55 years (range, 18-91 years), and primarily comprised of surgeries including lower abdominal and orthopedic bone procedures) using a standard intravenous patient controlled analgesia (PCA) morphine regimen as the comparator. In these studies, 1313 patients undergoing major surgery were randomized to PCA with intravenous morphine (1 mg morphine bolus, 5 minute lock-out, total of 10 mg/h) delivered by a pump, and 1288 patients were randomized to Дюрогезик Матрикс. Similar to the placebo-controlled studies, in the immediate postoperative period, patients were titrated to comfort with intravenous fentanyl or morphine per hospital protocol. Once comfortable, patients were then randomized to either Дюрогезик Матрикс or intravenous PCA morphine treatment. Patients were instructed to use the system for pain relief.
These studies evaluated Дюрогезик Матрикс vs. intravenous PCA morphine in various surgical procedures commonly seen in clinical practice. Study C-2000-007 evaluated patients after undergoing abdominal, thoracic, or orthopedic surgeries; Study CAPSS-319 evaluated patients after undergoing total hip replacement; Study CAPSS-320 assessed Дюрогезик Матрикс in patients following abdominal and pelvic surgeries; and Study FEN-PPA-401 assessed patients following major abdominal or orthopedic surgery. Patients could remain in their respective study up to 72 hours if they required parenteral opioid analgesia for this duration. A new Дюрогезик Матрикс system was applied every 24 hours to different skin sites, or earlier if all doses were used. Supplemental intravenous opioid medication (fentanyl or morphine) was only allowed during the first 3 hours of Дюрогезик Матрикс or PCA morphine treatment. Concomitant use of analgesics was not allowed after 3 hours in Studies C-2000-007 and CAPSS-320. In Study CAPSS-319, half the patients in each group received rofecoxib perioperatively and in Study FEN-PPA-401 patients were allowed non-opioid analgesics throughout the study period. The primary efficacy endpoint was the patient global assessment of method of pain control at 24 hours used to test equivalence between Дюрогезик Матрикс and intravenous PCA morphine using a pre-specified ± 10% equivalence boundary with a 2-sided 95% confidence interval. Each patient and investigator was asked to rate the patient's method of pain control as either poor, fair, good, or excellent. Efficacy results at the end of 24 hours, are presented in Table 2 below for the evaluable patient population. As shown below, the primary endpoint, proportion of patients reporting “Good or Excellent†ratings for the two methods of pain relief in all four studies demonstrated equivalence, with each 95% confidence interval contained within the prespecified ± 10% equivalence boundaries.
Table 2
Active Comparator Trials (n=2569) Evaluable Patients
| Study No. | Дюрогезик Матрикс (fentanyl) n=1271 | IV-PCA (morphine) n=1298 | 95% CIa, b |
| Patient Global Assessment of Method of Pain Control -1st 24 hour (% of patients rating good or excellent) | |||
| C-2000-007 | 75% (232/310) | 78% (246/316) | (-9.7%, 3.7%)a, b |
| CAPSS-319 | 84% (326/389) | 83% (331/397) | (-4.7%, 5.6%)a, b |
| CAPSS-320 | 86% (214/250) | 85% (212/251) | (-5.1%, 7.4%)a, b |
| FEN-PPA-401 | 87% (279/322) | 88% (293/334) | (-6.2%, 4.0%)a, b |
a 95% Confidence Interval for difference in proportions
b The pre-specified equivalence boundary was ± 10%
Across the active-controlled studies, dosing with Дюрогезик Матрикс was similar to intravenous PCA morphine pump use. The mean amount of supplemental opioid used during this time was also similar among patients treated with Дюрогезик Матрикс or PCA morphine i.e. a range across the 4 studies of a mean dose of 5.0 - 7.5 mg morphine in patients treated with Дюрогезик Матрикс compared to a mean dose of 5.4 - 7.7mg morphine in patients receiving PCA morphine.. Patients who completed 24 hours of Дюрогезик Матрикс treatment in the seven controlled studies used a wide range of the available 80 doses, with a mean of 29.0 doses/patient (range of 0-93 doses) with the majority of patients (56.5%) using between 11 to 50 doses. A single Дюрогезик Матрикс system provided a sufficient number of doses for 99% of the studied patients over 24 hours.
Paediatric population
The European Medicines Agency has deferred the obligation to submit the results of studies with Дюрогезик Матрикс in one or more subsets of the paediatric population for the treatment of acute pain.
Absorption
At the initiation of each dose, an electrical current moves a pre-determined amount of fentanyl from the active substance-containing reservoir through the skin and into systemic circulation. Дюрогезик Матрикс delivers a nominal dose of 40 micrograms fentanyl over each 10-minute dosing period at steady state. The mean systemic bioavailability is 87%. Upon system removal after the last dose, the decline in serum fentanyl concentration is similar to that of intravenous fentanyl.
Absorption of fentanyl from Дюрогезик Матрикс is similar whether applied to the upper outer arm or chest. When the system is applied on the lower inner arm, the amount of fentanyl absorbed is approximately 20% lower than at the upper outer arm or chest. Fentanyl pharmacokinetics are similar with both single and multiple 24 hour applications.
Systemic absorption of fentanyl increases as a function of time independent of the frequency of dosing, with the initial dose being approximately 16 micrograms. Steady state absorption of the nominal 40 microgram dose is achieved about 12 hours after application, indicating that the skin becomes more permeable to fentanyl during the first 12 hours. The pharmacokinetic absorption profile will repeat with each application to a new skin site, therefore with each new application, absorption will be lower initially. Consequently, the patient may activate Дюрогезик Матрикс more frequently to maintain fentanyl blood levels.
When Дюрогезик Матрикс is applied without activating the electrical current, the average absorption rate of fentanyl over 24 hours was 2.3 micrograms fentanyl/hour, indicating minimal passive delivery.
Average serum concentrations observed in post-surgical patients were in the range of 0.4-1.5 ng/ml over a 24 hour dosing period. In general, the maximum serum fentanyl concentration occurs approximately 15 minutes after the initiation of a dose.
Following an on-demand dose of fentanyl by Дюрогезик Матрикс, fentanyl has an absorption half-life of approximately 15 minutes.
Distribution
Fentanyl is highly lipophilic and is well distributed beyond the vascular system, with a large apparent volume of distribution. Fentanyl exhibits three compartment distribution pharmacokinetics. With intravenous administration, the initial distribution half-life is approximately 6 minutes; the second distribution half-life is 1 hour, and the terminal half-life is 13 hours. The plasma protein binding of fentanyl is 80% to 85%. The main binding protein is alpha-1-acid glycoprotein, but both albumin and lipoproteins contribute to some extent. The free fraction of fentanyl increases with acidosis.
The average volume of distribution for fentanyl at steady state is 6 L/kg, the average clearance is 53 L/h.
Biotransformation
Fentanyl is metabolised primarily in the liver to norfentanyl by CYP3A4 isoform. Norfentanyl is not pharmacologically active in animal studies. More than 90% of the administered dose of fentanyl is eliminated by biotransformation to N-dealkylated and hydroxylated inactive metabolites. Skin does not appear to metabolise fentanyl delivered transdermally.
Elimination
Around 75% of fentanyl is excreted into the urine, mostly as metabolites, with less than 10% as unchanged active substance. About 9% of the dose is recovered in the faeces, primarily as metabolites. The total plasma clearance of fentanyl following intravenous administration is approximately 42 L/h
Linearity/non-linearity
Dose proportionality has been demonstrated from 25 to 60 micrograms per dose.
None of the four demographic factors studied [weight (lean/obese), age, race, or gender] had a significant effect on active substance exposure (AUC) following use of Дюрогезик Матрикс.
Pharmacokinetic /pharmacodynamic relationship
Minimum effective analgesic serum concentrations of fentanyl in opioid-naïve patients treated for acute post-operative pain range from 0.2 to 1.2 ng/ml; undesirable effects increase in frequency at serum levels above 2 ng/ml.
Patients with genetic polymorphisms affecting CYP3A4 and CYP3A5
Published literature has indicated that the CYP3A4*22 and CYP3A5*3 single nucleotide polymorphisms influence fentanyl to norfentanyl metabolism with the potential for increased fentanyl exposure in patients with these genetic polymorphs. Literature has shown that the genetic polymorphisms only account for a small amount of variability in concentrations of fentanyl with transdermal administration. Another published article of 52 elderly Japanese post-operative patients receiving continuous intravenous (IV) fentanyl infusion (0.5-1.5 µg/kg/h) showed increased fentanyl exposure in the CYP3A5*3 group (3*/3*) than in the 1* carrier group. Clinical relevance is unknown from these published articles; however, caution should be used if administering Дюрогезик Матрикс in patients with genetic polymorphisms of CYP3A4 and CYP3A5.
Before any surgery, the healthcare professional should ensure that the patient has been properly informed on how to use Дюрогезик Матрикс post-operatively.
A potentially dangerous amount of fentanyl remains in the Дюрогезик Матрикс system after use.
Дюрогезик Матрикс should be removed before a magnetic resonance imaging (MRI) procedure, cardioversion, defibrillation, X-ray, CT scan or diathermy is undertaken.
Excessive sweating may reduce delivery of fentanyl.
Respiratory depression
Дюрогезик Матрикс should only be activated by the patient, to avoid potential overdosing.
Significant respiratory depression may occur with Дюрогезик Матрикс; patients must be observed for these effects.
The use of concomitant CNS-active medicinal products may increase the risk of respiratory depression.
Chronic pulmonary disease
In patients with chronic obstructive pulmonary disease or patients with conditions pre-disposing them to hypoventilation, more severe adverse reactions may be experienced. In such patients, opioids may decrease respiratory drive and increase airway resistance.
Head injuries and increased intracranial pressure
Fentanyl should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. Opioids may obscure the clinical course of patients with head injury. Fentanyl should be used with caution in patients with brain tumours or other significant space occupying lesions of the brain.
Cardiac disease
Fentanyl may produce bradycardia or hypotension and should, therefore, be administered with caution to patients with bradyarrhythmias or any significant cardiovascular disease.
Paralytic ileus
Дюрогезик Матрикс should be used with caution in patients with paralytic ileus.
Abuse potential and dependence
Fentanyl has a well-known abuse potential. Patients with a prior history of drug dependence/alcohol abuse are more at risk to develop dependence and abuse in opioid treatment. Physicians should evaluate patients for a history of drug abuse and follow such patients closely.
Tolerance, physical dependence, and psychological dependence may develop upon repeated administration of opioids. Iatrogenic addiction following opioid administration is rare. Fentanyl can be abused in a manner similar to other opioid agonists. Abuse or intentional misuse of Дюрогезик Матрикс may result in overdose and/or death.
Hepatic disease
Fentanyl is metabolised into inactive metabolites in the liver. Hepatic disease may delay elimination. Patients with hepatic impairment should be observed carefully for signs of fentanyl toxicity.
Renal disease
Less than 10% of administered fentanyl is excreted unchanged by the kidney. Unlike morphine, no active fentanyl metabolites are eliminated by the kidney. Data obtained with intravenous fentanyl in patients with renal failure suggest that the volume of distribution of fentanyl may be changed by dialysis. This may affect serum concentrations. If patients with renal impairment receive Дюрогезик Матрикс, they should be observed carefully for signs of fentanyl toxicity.
Elderly patients
Elderly patients should be observed carefully for adverse effects of fentanyl during Дюрогезик Матрикс administration.
Obese patients
The overall adverse reaction profile for morbidly obese patients (BMI > 40) does not suggest a meaningful difference in safety compared to patients with BMI ≤ 40. However, caution is advised when prescribing Дюрогезик Матрикс in morbidly obese patients because they may be at increased risk of other comorbid respiratory conditions (i.e., sleep apnoea) potentially pre-disposing them to hypoventilation or more severe adverse reactions.
Hearing impairment
Дюрогезик Матрикс should be used with caution in patients with hearing impairment who might not be able to hear the audible signals from the system.
Thoracic/chest and upper abdominal surgeries
Only limited data are available in patients with thoracic/chest and upper abdominal surgeries. Дюрогезик Матрикс should, therefore, be used with caution in these patients.
Physical status
The safety of Дюрогезик Матрикс has not been established in patients with American Society of Anesthesiologists (ASA) physical status classification IV (i.e. patients with a severe systemic disease that is a constant threat to life).
Patients with genetic polymorphisms affecting CYP3A4 and CYP3A5
Published literature indicates potential for increased fentanyl exposure in patients with genetic polymorphisms affecting CYP3A4 and CYP3A5, with a small variability in concentrations with transdermal administration; therefore, Дюрогезик Матрикс should be used with caution in these patients
Opioid analgesics impair the mental and/or physical ability required for the performance of potentially dangerous tasks (e.g., driving a car or operating machinery). Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, or visual disturbance.
Дюрогезик Матрикс is restricted to hospital use only. Treatment should be initiated by and remain under the guidance of a physician experienced in the management of opioid therapy. Due to the well-known potential of abuse of fentanyl, physicians should evaluate patients for a history of drug abuse.
Posology
Patients should be titrated to an acceptable level of analgesia prior to initiating use of Дюрогезик Матрикс.
Дюрогезик Матрикс should only be activated by the patient.
Each dose of Дюрогезик Матрикс delivers 40 micrograms of fentanyl over a 10 minute period, to a maximum of 240 micrograms per hour (6 doses each of 10 minutes duration). Дюрогезик Матрикс will operate for 24 hours after the system is assembled or for 80 doses, whichever comes first, and then becomes inoperative.
After 24 hours or 80 doses, a new system should be applied if necessary. Each new system should be placed on a new skin site. With each new Дюрогезик Матрикс application the patient may use Дюрогезик Матрикс more frequently than during the remainder of the 24 hour dosing period, due to a lower absorption of fentanyl from the system for the first few hours.
The maximum treatment duration is 72 hours, although the majority of patients should only need one system.
Patients should not wear more than one system at a time.
Used systems should not be reapplied to a patient.
Дюрогезик Матрикс should be removed before the patient is discharged.
Elderly patients
As with all fentanyl products, the clearance of fentanyl may be reduced in elderly patients, with a consequent increase in half life. No specific dose adjustment is required in elderly patients. However elderly patients should be observed closely for adverse effects of fentanyl.
Hepatic or renal impairment
Дюрогезик Матрикс should be administered with caution to patients with moderate or severe hepatic or renal impairment.
Paediatric population
The safety and efficacy of Дюрогезик Матрикс in children and adolescents younger than 18 years of age has not been established.
Method of administration
Дюрогезик Матрикс is for transdermal use only.
Precaution to be taken before manipulating or administering the product
Gloves should be worn when manipulating Дюрогезик Матрикс. To avoid oral ingestion of the fentanyl-containing hydrogel, which may cause life-threatening hypoventilation or death, the hydrogel must not touch the mouth or other mucosal areas.
Patients should not get Дюрогезик Матрикс wet. Prolonged contact with water could affect system performance and cause the system to fall off.
Preparation of application site
Дюрогезик Матрикс should be applied to intact, non-irritated and non-irradiated skin. Дюрогезик Матрикс should not be placed on abnormal skin sites, such as scars, burns, tattoos, etc. Дюрогезик Матрикс should also not be placed on skin on which topical medicines have been applied. Hair at the application site should be clipped (not shaved) before system application. Дюрогезик Матрикс should not be applied to a previously used skin site.
The application site should be wiped with a standard alcohol swab and the skin should be allowed to dry completely before Дюрогезик Матрикс is applied. No soaps, oils, lotions, or any other agents that might irritate the skin or alter its absorption characteristics should be used to clean the application site.
Assembly of Дюрогезик Матрикс
Дюрогезик Матрикс should not be used if the seal on the tray or the sachet containing the Drug Unit is broken or damaged.
Gloves should be worn during the assembly of Дюрогезик Матрикс. The tray is opened by pulling back on the tray lid. The sachet containing the Drug Unit should be opened starting at the pre-cut notch, then by carefully tearing along the top of the sachet. The Drug Unit should be removed from the sachet and the Controller should be snapped on by aligning the shape and firmly pressing the two parts together.
When assembled, the digital display of the Controller will complete a short self-test during which there will be an audible beep, the red light will flash once, and the digital display will flash the number 88. At the end of the self-test, the display will show the number 0 and a green light will flash at a slow rate to indicate Дюрогезик Матрикс is ready for application.
Application of Дюрогезик Матрикс
The clear plastic film covering the adhesive should be removed and discarded with care taken not to touch the hydrogels.
Dose delivery
A recessed dosing button is located on the Controller of Дюрогезик Матрикс. To initiate administration of a fentanyl dose, the patient should press and release the dosing button twice within 3 seconds. Дюрогезик Матрикс should only be activated by the patient.
Upon successful dose initiation, Дюрогезик Матрикс will emit a beep indicating the start of delivery. The green light will change from a slow flash rate to a rapid flash rate and the digital display will alternate between a rotating circle and the number of completed doses during the entire 10-minute dose delivery period. The next dose cannot be initiated until the previous 10-minute delivery period is complete. Pressing the button during delivery of a dose will not result in additional fentanyl being administered. After the 10-minute dose has been completely delivered, the green light will return to a slow flash rate, the digital display will show the number of doses that have been delivered, and Дюрогезик Матрикс will be ready to be used again by the patient.
At the end of 24 hours of use, or after 80 doses have been administered, the green light will switch off and the number of doses delivered will flash on and off. The flashing digital display may be turned off by pressing the dose button for six seconds.
Removal
Дюрогезик Матрикс is removed from the patient by lifting the system at the red tab and peeling it away from the skin site. Gloves must be worn while removing Дюрогезик Матрикс from the skin and care should be taken to avoid touching the hydrogels. If the medicinal product contacts the skin during removal, the contact area should be thoroughly rinsed with water without using any soap.
Дюрогезик Матрикс may be removed at any time. However, once a system has been removed, the same system should not be reapplied. If the patient requires additional treatment for pain, a new system may be applied to a new skin site on the upper outer arm or chest.
Special precautions for disposal should be followed.
Troubleshooting
Each Дюрогезик Матрикс system is designed to deliver up to 80 10-minute doses of fentanyl over a period of 24 hours. The table below represents the different error messages that may occur, together with the probable cause and the action to be taken.
| Error message/feedback | Probable cause | Action required |
| - No light - No beeps - No display | Low battery or defective system | 1. Do not use the system 2. 3. Place a new system on a different skin site |
| - Blinking red light for 15 seconds - Beeping for 15 seconds - System is not securely adhered | Poor skin contact | 1. Secure system to patient's skin by pressing the edges firmly or by applying non-allergenic tape 2. If system beeps again, then remove and dispose of system, and place a new system on a different skin site. |
| - Continuous blinking red light - Continuous beeping - Steady display number | System error | 1. Remove system from patient 2. Hold down dosing button until beeping stops and display goes blank 3. 4. Place a new system on a different skin site |
| - No light - No beeps - Blinking display number | End of use at 24 hours or 80 doses | 1. Remove system from patient 2. Hold down dosing button until display goes blank 3. 4. Place a new system on a different skin site |
If device failure or malfunction is suspected by a healthcare professional, Дюрогезик Матрикс should be immediately removed from the patient and The Medicines Company contacted straightaway.
The healthcare professional must ensure the patient understands that if they suspect a device failure or malfunction, they must immediately inform a healthcare professional.
Contact with the hydrogel can be harmful to humans. If the fentanyl hydrogel contacts the skin during application or removal, the area should be washed with copious amounts of water. Soap, alcohol, or other solvents should not be used to remove the hydrogel because they may enhance the active substances' ability to penetrate the skin.
Disposal
The used Дюрогезик Матрикс system contains a dangerous amount of fentanyl within the red hydrogel housing. Gloves must be worn when removing Дюрогезик Матрикс from the patient's skin and during disposal. The used system should be handled carefully by the sides and top. Contact with the hydrogel should be avoided.
The design of the system allows separate disposal of the hydrogel housing and the Controller.
To dispose of a used Дюрогезик Матрикс system:
1. Hold the Controller in one hand and pull the red tab with the other hand to separate the hydrogel housing from the system.
2. Fold the hydrogel housing in half with the sticky side facing in.
3. Dispose of the folded hydrogel housing in accordance with local requirements for opioid medicinal products.
4. Dispose of remainder of the system, containing electronics, according to hospital procedures for battery waste.
Local arrangements should be in place to ensure that used systems are returned appropriately (e.g., to hospital pharmacies) for disposal of the residual fentanyl in the hydrogel. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
